Humacyte, Inc. (HUMA) Tops Q2 EPS by 57c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Humacyte Second Quarter 2022 Financial Results and Business Update
August 12, 2022 7:00 AM EDT-- Human Acellular Vessels (HAVs) successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs
-- Hosted key opinion leader (KOL) webinar on HAV in the treatment of vascular trauma, featuring Ernest E. Moore, M.D and Gregory A. Magee, M.D.
-- Strengthened Board of Directors with appointment of Diane Seimetz, Ph.D. and leadership team with appointment of Shamik Parikh, M.D. as Chief Medical Officer
 -- Multiple scientific meeting presentations and publications highlighting clinical HAV data in vascular... More
